NO20062401L - Anvendelse av et hydroksimsyrehalidderivat i behandling av neurodegenerative sykdommer - Google Patents

Anvendelse av et hydroksimsyrehalidderivat i behandling av neurodegenerative sykdommer

Info

Publication number
NO20062401L
NO20062401L NO20062401A NO20062401A NO20062401L NO 20062401 L NO20062401 L NO 20062401L NO 20062401 A NO20062401 A NO 20062401A NO 20062401 A NO20062401 A NO 20062401A NO 20062401 L NO20062401 L NO 20062401L
Authority
NO
Norway
Prior art keywords
treatment
neurodegenerative diseases
acid halide
halide derivative
hydroxymic acid
Prior art date
Application number
NO20062401A
Other languages
English (en)
Inventor
Linda Greensmith
Geoffrey Burnstock
Rudolf Urbanics
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corp filed Critical Cytrx Corp
Publication of NO20062401L publication Critical patent/NO20062401L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen vedrører anvendelsen av en kjemisk substans valgt fra gruppen som består av N-[2-hydroksy-3-(l-piperidinyl)-propoksy]-pyridin-l-oksyd-3-karboksimidoyI klorid. De optisk aktive enantiomeren og blandingene av enantiomerene av den og farmasøytisk akseptable salter av de racemiske og optisk aktive forbindelsen i tillagingen av en farmasøytisk sammensetning for behandlingen eller forebyggingen av neurodegenerative sykdommer.
NO20062401A 2003-10-30 2006-05-26 Anvendelse av et hydroksimsyrehalidderivat i behandling av neurodegenerative sykdommer NO20062401L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0303584A HUP0303584A3 (en) 2003-10-30 2003-10-30 Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
PCT/HU2004/000098 WO2005041965A1 (en) 2003-10-30 2004-10-25 Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
NO20062401L true NO20062401L (no) 2006-07-27

Family

ID=89981738

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062401A NO20062401L (no) 2003-10-30 2006-05-26 Anvendelse av et hydroksimsyrehalidderivat i behandling av neurodegenerative sykdommer

Country Status (27)

Country Link
US (3) US20080039497A1 (no)
EP (2) EP2020233A3 (no)
JP (1) JP5077997B2 (no)
KR (1) KR20060103323A (no)
CN (1) CN1901913A (no)
AT (1) ATE409038T1 (no)
AU (1) AU2004285343B2 (no)
BR (1) BRPI0415625A (no)
CA (1) CA2544332C (no)
CY (1) CY1110450T1 (no)
CZ (1) CZ2006347A3 (no)
DE (1) DE602004016770D1 (no)
DK (1) DK1696922T3 (no)
EA (1) EA011301B1 (no)
ES (1) ES2314458T3 (no)
HK (1) HK1097438A1 (no)
HR (1) HRP20080660T3 (no)
HU (1) HUP0303584A3 (no)
IL (1) IL175334A (no)
NO (1) NO20062401L (no)
NZ (1) NZ547216A (no)
PL (1) PL1696922T3 (no)
PT (1) PT1696922E (no)
SI (1) SI1696922T1 (no)
UA (1) UA86782C2 (no)
WO (1) WO2005041965A1 (no)
ZA (1) ZA200604376B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533795A (en) 2002-01-11 2006-03-31 Biorex Kutato Fejlesztoe Kft Carboxamidine derivatives and their use in the treatment of vascular diseases
WO2008039514A1 (en) * 2006-09-26 2008-04-03 Cytrx Corporation Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
CA2728363C (en) 2008-06-26 2019-02-19 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
CN102215842A (zh) 2008-11-18 2011-10-12 参天制药株式会社 含有吡啶-3-甲醛o-(哌啶-1-基-丙基)-肟衍生物作为有效成分的脉络膜视网膜变性疾病的治疗剂
AU2011335545A1 (en) 2010-11-30 2013-06-13 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
HUP1100534A2 (en) * 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
CN103804309B (zh) * 2012-11-09 2019-08-02 广州喜鹊医药有限公司 一种氯肟类化合物及其制备方法和在制药中的应用
PT3193840T (pt) * 2014-09-15 2021-08-10 Orphazyme Aps Formulação de arimoclomol
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
KR102254140B1 (ko) * 2016-04-29 2021-05-24 오르파짐 에이/에스 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
AU2018274176A1 (en) 2017-05-24 2020-01-16 Zevra Denmark A/S Heat shock protein inducers and frontotemporal disorders
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177578B (en) 1976-08-27 1981-11-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives
DE2651083A1 (de) 1976-11-09 1978-05-18 Hoechst Ag Neue o-alkylierte hydroxylamine, verfahren zu ihrer herstellung und ihre verwendung
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
US5334600A (en) * 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
ES2123252T3 (es) 1994-05-06 1999-01-01 Biorex Kutato Fejlesztoe Kft Nuevos derivados de acido hidroximico, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
UA64716C2 (en) 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ
HUP9900475D0 (en) * 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
ITMI20012573A1 (it) 2001-12-06 2003-06-06 D B P Dev Biotechonologica L P Gli acilsalicilati:una nuova classe di induttori di risposta heat shock

Also Published As

Publication number Publication date
DK1696922T3 (da) 2008-12-01
HU0303584D0 (en) 2003-12-29
US20080039497A1 (en) 2008-02-14
ES2314458T3 (es) 2009-03-16
PT1696922E (pt) 2008-10-17
JP5077997B2 (ja) 2012-11-21
CY1110450T1 (el) 2015-04-29
KR20060103323A (ko) 2006-09-28
HUP0303584A3 (en) 2009-12-28
CN1901913A (zh) 2007-01-24
UA86782C2 (ru) 2009-05-25
EA011301B1 (ru) 2009-02-27
AU2004285343B2 (en) 2010-05-13
HK1097438A1 (en) 2007-06-29
EP1696922A1 (en) 2006-09-06
EP2020233A2 (en) 2009-02-04
WO2005041965A1 (en) 2005-05-12
NZ547216A (en) 2009-03-31
US20150126551A1 (en) 2015-05-07
BRPI0415625A (pt) 2006-12-12
IL175334A (en) 2010-12-30
DE602004016770D1 (de) 2008-11-06
CA2544332A1 (en) 2005-05-12
PL1696922T3 (pl) 2009-03-31
IL175334A0 (en) 2008-04-13
HUP0303584A2 (hu) 2005-12-28
US8962604B2 (en) 2015-02-24
CZ2006347A3 (cs) 2006-10-11
AU2004285343A1 (en) 2005-05-12
EP1696922B1 (en) 2008-09-24
ATE409038T1 (de) 2008-10-15
SI1696922T1 (sl) 2008-12-31
ZA200604376B (en) 2009-04-29
EP2020233A3 (en) 2009-09-30
HRP20080660T3 (en) 2009-01-31
EA200600866A1 (ru) 2006-10-27
US20120115908A1 (en) 2012-05-10
JP2007509920A (ja) 2007-04-19
CA2544332C (en) 2014-09-23

Similar Documents

Publication Publication Date Title
NO20062401L (no) Anvendelse av et hydroksimsyrehalidderivat i behandling av neurodegenerative sykdommer
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20052914L (no) Terapeutiske forbindelser
NO20032734D0 (no) Nye 1,2-difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder nevnte forbindelser og anvendelse avdisse for behandling av sykdommer fra lipidstoffskiftet
ATE484494T1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
NO20060342L (no) 1-sulfonylindol derivater, deres fremstilling og deres andvendelse som 5-HT6 ligander
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
NO20090328L (no) Nye forbindelser 385
ES2193875A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
SE9901573D0 (sv) New compounds
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
ATE332894T1 (de) Ein pyridin-n-oxid-derivat und ein prozess zu seiner umsetzung in pharmazeutische wirkstoffe
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
HUP0204520A2 (en) Pharmaceutical composition containing esmolol and process for its preparation
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
HRP20050831A2 (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
SE9901572D0 (sv) New compounds
DK0911026T3 (da) Creatinderivater for astma
DE602005017629D1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
NO20054495L (no) Nye anilinderivater, deres fremstilling og anvendelse som farmasoytiske forbindelser
SE9900190D0 (sv) New compounds
RU2009120137A (ru) Дмаэ (dmae) как единственное средство для лечения умеренного когнитивного нарушения
HUP0002905A2 (hu) 2-{4-[4-(4,5-Diklór-2-metilimidazol-1-il)butil]1-1piperazinil}-5-fluorpirimidin, előállítása és gyógyászati alkalmazása

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application